How do serum lipid levels change and influence progression-free survival in epithelial ovarian cancer patients receiving bevacizumab treatment?

How do serum lipid levels change and influence progression-free survival in epithelial ovarian cancer patients receiving bevacizumab treatment?

BackgroundThis study aimed to investigate how serum lipid levels affect epithelial ovarian cancer (EOC) patients receiving bevacizumab treatment and to develop a model for predicting the patients’ prognosis.MethodsA total of 139 EOC patients receiving bevacizumab treatment were involved in this stud...

Full description

Bibliographic Details
Main Authors:	Xiaoyu Huang, Yong Huang, Ping Li
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-03-01
Series:	Frontiers in Oncology
Subjects:	epithelial ovarian cancer serum lipid level change influence progression free survival bevacizumab treatment
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2023.1168996/full

Similar Items

Bevacizumab with Chemotherapy as a First-Line Treatment for Advanced Ovarian Cancer in a Serbian Cohort
by: Irena Conic, et al.
Published: (2022-04-01)

Real-World Efficacy of Bevacizumab in Patients With Recurrent Epithelial Ovarian Cancer
by: Jo-Ni Hung, et al.
Published: (2022-05-01)

Bevacizumab in maintenance therapy for ovarian cancer patients
by: L. Yu. Vladimirova, et al.
Published: (2020-08-01)

Impact of diabetes mellitus on epithelial ovarian cancer survival
by: Setareh Akhavan, et al.
Published: (2018-12-01)

An open-label, randomized, phase II trial evaluating the efficacy and safety of standard of care with or without bevacizumab in platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer patients previously treated with bevacizumab for front-line or platinum-sensitive ovarian cancer: rationale, design, and methods of the Japanese Gynecologic Oncology Group study JGOG3023
by: Tadahiro Shoji, et al.
Published: (2018-07-01)

Associations of novel serum lipid index with epithelial ovarian cancer chemoresistance and prognosis
by: Yuan Li, et al.
Published: (2023-02-01)

Real-World Experience of Bevacizumab as First-Line Treatment for Ovarian Cancer: The GINECO ENCOURAGE Cohort of 468 French Patients
by: Dominique Berton, et al.
Published: (2021-09-01)

Cetuximab versus bevacizumab following prior FOLFOXIRI and bevacizumab in postmenopausal women with advanced KRAS and BRAF wild-type colorectal cancer: a retrospective study
by: Chunlong Huang, et al.
Published: (2021-01-01)

Real-World Study of Adding Bevacizumab to Chemotherapy for Ovarian, Tubal, and Peritoneal Cancer as Front-Line or Relapse Therapy (ROBOT): 8-Year Experience
by: Pei-Ying Wu, et al.
Published: (2020-07-01)

Influence of lymphadenectomy on survival and recurrence in patients with early-stage epithelial ovarian cancer: a meta-analysis
by: Chenchen Yang, et al.
Published: (2023-09-01)

Effect of bevacizumab combined with chemotherapy on SDF-1 and CXCR4 in epithelial ovarian cancer and its prognosis
by: Chunyan Ma
Published: (2022-05-01)

Combination of pemetrexed with bevacizumab for non-small-cell lung cancer: a meta-analysis study
by: Wei Fang, et al.
Published: (2024-08-01)

Re-treatment with PARPi in patients with recurrent epithelial ovarian cancer: A single institutional experience
by: Malak Moubarak, et al.
Published: (2022-04-01)

Modified Intraperitoneal Chemotherapy Without Bevacizumab as a First-Line Therapy for Newly Diagnosed Advanced Epithelial Ovarian Cancer-Two Centers Experiences
by: Yuanming Shen, et al.
Published: (2022-03-01)

Development and External Validation of a Novel Model for Predicting Postsurgical Recurrence and Overall Survival After Cytoreductive R0 Resection of Epithelial Ovarian Cancer
by: Qiaqia Li, et al.
Published: (2022-03-01)

Bevacizumab as a mitigating factor for the impact of high systemic immune-inflammation index on chemorefractory in advanced epithelial ovarian cancer
by: Yan-Ping Fu, et al.
Published: (2024-11-01)

Bevacizumab for the Treatment of High-Grade Meningiomas: Is There New Evidence? [Letter]
by: da Silva VTG, et al.
Published: (2022-10-01)

Efficacy of Bevacizumab in High-Grade Meningiomas: A Retrospective Clinical Study
by: Bai X, et al.
Published: (2022-08-01)

Efficacy of hyperthermic intraperitoneal chemotherapy in patients with epithelial ovarian cancer: a meta-analysis
by: Qiwen Wu, et al.
Published: (2019-01-01)

Cisplatin-based chemotherapy with or without bevacizumab for Chinese postmenopausal women with advanced cervical cancer: a retrospective observational study
by: Xiaoli He, et al.
Published: (2020-05-01)

Survival prediction using apparent diffusion coefficient values in recurrent glioblastoma under bevacizumab treatment: an updated systematic review and meta-analysis
by: Dong Liu, et al.
Published: (2024-07-01)

Improved clinical outcomes in advanced hepatocellular carcinoma treated with transarterial chemoembolization plus atezolizumab and bevacizumab: a bicentric retrospective study
by: Fei Cao, et al.
Published: (2023-09-01)

Neutrophil-to-Lymphocyte Ratio and Platelet Count Predict Long-Term Outcome of Stage IIIC Epithelial Ovarian Cancer
by: Mingyi Zhou, et al.
Published: (2018-03-01)

Biomarker Assessment of Homologous Recombination Deficiency in Epithelial Ovarian Cancer: Association With Progression-Free Survival After Surgery
by: Huan Yi, et al.
Published: (2022-06-01)

Capecitabine plus bevacizumab versus capecitabine in maintenance treatment for untreated characterised KRAS exon 2 wild-type metastatic colorectal cancer: a retrospective analysis in Chinese postmenopausal women
by: Jinsong Su, et al.
Published: (2019-01-01)

Germline and Somatic BRCA1/2 Mutations in 172 Chinese Women With Epithelial Ovarian Cancer
by: Yan You, et al.
Published: (2020-03-01)

Dose and Efficacy of Bevacizumab in Recurrent High-Grade Gliomas: A Retrospective Study
by: Bai X, et al.
Published: (2024-11-01)

Expression and clinical significance of NCOA5 in epithelial ovarian cancer
by: Xiaoping Song, et al.
Published: (2023-05-01)

Experience of using chemotherapy treatment for the first recurrence of ovarian cancer
by: V. N. Zhurman
Published: (2025-01-01)

Clinical case use bevacizumab for patient with metastatic ovarian cancer
by: M. R. Oganyan, et al.
Published: (2014-07-01)

Pre-treatment nutrition-related indicators and the prognosis of patients with newly diagnosed epithelial ovarian cancer: an ambispective cohort study
by: Shirui Wang, et al.
Published: (2025-01-01)

Characterization of DOK1, a candidate tumor suppressor gene, in epithelial ovarian cancer
by: Pierre-Luc Mercier, et al.
Published: (2011-10-01)

Keratin-15 high expression links with lymph node metastasis and poor survival prognosis in epithelial ovarian cancer patients
by: Xuqin Feng, et al.
Published: (2024-10-01)

Adipocytes: active facilitators in epithelial ovarian cancer progression?
by: Lan Dai, et al.
Published: (2020-09-01)

Editorial: Molecular physiopathology of epithelial ovarian cancer: role of inflammation
by: Gitana Maria Aceto, et al.
Published: (2024-01-01)

Prognostic performance of pretreatment systemic immune-inflammation index in women with epithelial ovarian cancer
by: Kehinde S Okunade, et al.
Published: (2023-12-01)

Can complete blood count inflammatory parameters in epithelial ovarian cancer contribute to prognosis? - a survival analysis
by: Mehmet Ufuk Ceran, et al.
Published: (2019-02-01)

Do ethnic chinese older adults with epithelial ovarian cancer survive a poorer prognosis?
by: Wu Huang, et al.
Published: (2023-06-01)

Gastrointestinal perforation after bevacizumab: a multi-site, single-institution study with a focus on survival
by: Michael H. Storandt, et al.
Published: (2023-06-01)

Body composition and inflammation variables as the potential prognostic factors in epithelial ovarian cancer treated with Olaparib
by: Xingzi Guo, et al.
Published: (2024-04-01)